Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
Authors: Kiat Ruxrungtham
Surapol Suwanagool
Jorge A. Tavel
Mena Chuenyam
Eugene Kroon
Sasiwimol Ubolyam
Supranee Buranapraditkun
Wichai Techasathit
Yeuming Li
Sean Emery
Richard T. Davey
Lisa Fosdick
Chaiyos Kunanusont
H. Clifford Lane
Praphan Phanuphak
Chulalongkorn University
Mahidol University
National Institute of Allergy and Infectious Diseases
University of Amsterdam
Kirby Institute
University of Minnesota Twin Cities
Thailand Ministry of Public Health
Thai Red Cross AIDS Research Centre
Keywords: Immunology and Microbiology;Medicine
Issue Date: 27-Nov-2000
Citation: AIDS. Vol.14, No.16 (2000), 2509-2513
Abstract: Objectives: To assess the immunological and virological effects, safety profile and feasibility of subcutaneous interleukin-2 (sclL-2) therapy in an HIV-infected Thai population. Design: Seventy-two patients with baseline CD4 cell count of ≥ 350 x 106/l and no history of opportunistic infection were randomized to receive antiretroviral therapy plus scIL-2 (scIL-2 group) or antiretroviral therapy alone (control group). scIL-2 was administered at one of three doses for at least 24 weeks. The main measure of treatment efficacy was change in CD4 cell count. Results: The time-weighted mean change in CD4 cell count from baseline to week 24 was + 252 x 106/l for the scIL-2 group compared with + 42 x 106/l for the control group (P< 0.0001). Changes in plasma HIV RNA were not significantly different between the groups over the same time period: there was a 0.83 log10 copies/ml decrease for the sclL-2 group and a 0.70 log copies/ml decrease for the control group (P = 0.362). Conclusions: This study provides the most extensive experience of sclL-2 therapy in HIV-1 infected women and Asians, and demonstrates the immunological efficacy, tolerability and feasability of sclL-2 therapy in this population. Data from this study were instrumental in guiding the selection of the sclL-2 dosing regimen for ongoing phase III trials. (C) 2000 Lippincott Williams and Wilkins.
ISSN: 02699370
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.